Carra S, Gaudenzi G. New perspectives in neuroendocrine neoplasms research from tumor xenografts in zebrafish embryos. Minerva Endocrinol. 2020; 45:393–4.
Garcia-Carbonero R, Sorbye H, Baudin E, Raymond E, Wiedenmann B, Niederle B, et al. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology. 2016; 103:186–14.
Ferolla P, Faggiano A, Mansueto G, Avenia N, Cantelmi MG, Giovenali P, et al. The biological characterization of neuroendocrine tumors: The role of neuroendocrine markers. J. Endocrinol Investig. 2008; 31:277–86.
Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–8.
Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O’Dorisio TM, et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas 2020;49:863–81.
Caplin ME, Pavel M., Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 2014;37:1224–33.
Ricci C, Lamberti G, Ingaldi C, Mosconi C, Pagano N, Alberici L, et al. Treatment of advanced gastroentero-pancreatic neuro-endocrine tumors: A systematic review and network meta-analysis of phase III randomized controlled trials. Cancers. 2021;13:358.
Gaggero G, Bet P, Taietti D, Ingaliso M, Spina B. Retroperitoneal pararenal dedifferentiated liposarcoma with epithelioid/neuroendocrine features, somatostatin-positive. Forum Clin Oncol. 2022;13(1): 63–65.